Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
The platelet growth factor thrombopoietin, which is produced by the liver, has been shown to be decreased in patients with cirrhosis, and this deficit may contribute to the thrombocytopenia associated with hepatic disease
doi: 10.3389/fmolb.2025.1724944 Received 14 October 2025 Revised 18 November 2025 Accepted 30 November 2025 Published 18 December 2025 Volume 12 - 2025 Edited by Maria Barile, University of Bari Aldo Moro, Italy Reviewed by Anna Maria Giudetti, University of Salento, Italy Maria Tolomeo, National Research Council (CNR), Italy Updates Copyright 2025 Schrder, Jalilvand, Kahl, Kaiser and Liebau
Recommended Use: Mix 1 scoop (30g) with 200ml of water or milk
IGF-1 LR3's structural modifications allow it to remain unbound and biologically active for 2030 hours post-injection, delivering sustained systemic exposure to IGF-1 receptor signaling
